Oct. 12, 2022 |
|
April. 05, 2024 |
|
jRCTs062220063 |
Clinical study of patients with major depressive disorder and healthy participants to examine the usefulness of the brain network marker program using fMRI for the diagnosis and stratification of major depressive disorder |
|
Clinical study to examine the usefulness of the brain network marker program using fMRI for the diagnosis of major depressive disorder |
Okada Go |
||
Hiroshima University Hospital |
||
1-2-3 Kasumi,Minami-ku,Hiroshima City,Hiroshima 734-8551,Japan |
||
+81-82-257-5814 |
||
goookada@hiroshima-u.ac.jp |
||
Okada Go |
||
Hiroshima University |
||
1-2-3 Kasumi,Minami-ku,Hiroshima City,Hiroshima 734-8551,Japan |
||
+81-82-257-5814 |
||
goookada@hiroshima-u.ac.jp |
Recruiting |
Oct. 12, 2022 |
||
Oct. 24, 2022 | ||
390 | ||
Interventional |
||
non-randomized controlled trial |
||
open(masking not used) |
||
uncontrolled control |
||
single assignment |
||
diagnostic purpose |
||
[Patients] |
||
[Patients] |
||
20age old over | ||
75age old not | ||
Both |
||
Patients with major depressive disorder and healthy participants. |
||
For the escitalopram group, the study drug (Lexapro tablets or its generic products) will be used. We will conduct no pharmaceutical intervention in the usual care group, the cross-sectional study group, and the healthy participants group. |
||
AUC of ROC curves in discriminating between depressed and healthy groups calculated using depression diagnostic brain network markers. |
||
-Diagnostic brain network markers for major depressive disorder evaluated longitudinally (0w, 6w, 6m). |
XNef, Inc. | |
Applicable |
Japan Agency for Medical Research and Development | |
Not applicable |
Hiroshima University Certified Review Board | |
1-2-3 Kasumi,Minami-ku,Hiroshima City,Hiroshima 734-8551,Japan, Hiroshima | |
+81-82-257-1551 |
|
iryo-sinsa@office.hiroshima-u.ac.jp | |
Approval | |
Aug. 10, 2022 |
none |